Breaking News

Wacker Opens mRNA Competence Center in Germany

More than €100 million was invested in the Halle site and it is part of the German government's pandemic preparedness plan for vaccine supply.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Wacker has reached a milestone by opening an mRNA competence center at its biotech site in Halle (Saale), Germany. The new facility enables the large-scale production of active ingredients based on messenger ribonucleic acid (mRNA), such as anti-Covid mRNA vaccines. Wacker invested more than €100 million in this construction project, creating more than 100 jobs in Halle. Some of the new capacity will be made available to the German government as part of its pandemic-preparedness plan to rapid...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters